Page 9 - Skye Bioscience News Today

New collaborations focused on building library of novel cannabinoid derivatives and small molecules capable of modulating endocannabinoid system San Diego, California, June 07, 2022 -- Skye... | June 7, 2022

4:20pm: Target announcement drags on retail stocks The Dow closed Tuesday up 264 points, 0.8%, at 33,180, the Nasdaq improved 114 points, 0.9%, to 12,175...

4:20pm: Target announcement drags on retail stocks The Dow closed Tuesday up 264 points, 0.8%, at 33,180, the Nasdaq improved 114 points, 0.9%, to 12,175...

Skye Bioscience (OTCMKTS:SKYE – Get Rating) is one of 939 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare Skye Bioscience to similar companies based on the strength of its profitability, dividends, earnings, analyst recommendations, valuation, institutional ownership and risk. Analyst Recommendations This is […]

Arrangement is expected to fund Skye's proprietary synthetic cannabinoid-derivative therapeutic initially targeting glaucoma for first Phase 2 clinical study planned to start later in 2022Preclinical

Arrangement is expected to fund Skye’s proprietary synthetic cannabinoid-derivative therapeutic initially targeting glaucoma for first Phase 2 clinical...

Phunware Inc, the company behind a fully-integrated enterprise cloud platform for mobile that provides products, solutions, data and services for brands...

Skye Bioscience inc (OTCQB:SKYE) CEO Punit Dhillon tells Proactive that Skye and Emerald Health Therapeutics Inc (CSE:EMH, OTCQX:EMHTF) have entered into a...

Phunware Inc, the company behind a fully-integrated enterprise cloud platform for mobile that provides products, solutions, data and services for brands...

GuruFocus Article or News written by GuruFocusNews and the topic is about: